

**Patient Information**

Patient Name: \_\_\_\_\_  
 Date of Birth: \_\_\_\_\_ Sex: M or F Caregiver: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Home Phone: \_\_\_\_\_ Work Phone: \_\_\_\_\_  
 Cell Phone: \_\_\_\_\_ E-mail: \_\_\_\_\_  
 Please attach copy of front and back of patient's prescription ins. card(s) if applicable  
 Insurance Company Name: \_\_\_\_\_  
 Insurance Company Phone: \_\_\_\_\_  
 Policy Holder: \_\_\_\_\_  
 Policy Holder Employer: \_\_\_\_\_  
 Relationship to Patient: \_\_\_\_\_  
 ID#: \_\_\_\_\_ Group#: \_\_\_\_\_  
 RxBIN: \_\_\_\_\_ RxPCN: \_\_\_\_\_

**Prescriber Information**

Practice/Organization Name: \_\_\_\_\_  
 Physician Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone#: \_\_\_\_\_ Fax#: \_\_\_\_\_  
 DEA# \_\_\_\_\_ NPI# \_\_\_\_\_  
 License#: \_\_\_\_\_ Medicaid UPIN#: \_\_\_\_\_  
 Physician Specialty: \_\_\_\_\_  
 Date Shipment Needed: \_\_\_\_\_  
 Ship to:  Patient  Prescriber  Infusion Clinic  
 Shipment Address: \_\_\_\_\_ Attn: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
*If shipped to the physician's office, physician accepts on behalf of patient for administration in office.*

**Clinical Information and Prescription**

Diagnosis:  K51.\_\_\_\_ Ulcerative Colitis of the \_\_\_\_\_  
 Other: \_\_\_\_\_ ICD 10 Code: \_\_\_\_\_  
 Date of Diagnosis or Years with Disease: \_\_\_\_\_  
 Patients Allergies: \_\_\_\_\_  
 Latex allergy:  NO  YES  
 Patient Weight: \_\_\_\_\_ kg or lbs Patient Height: \_\_\_\_\_  
 Has the patient had a NEGATIVE tuberculin skin test?  YES  NO  
 Prior Medications and length of treatment: \_\_\_\_\_  
 Expected First Dose Date: \_\_\_\_\_ Injection Instruction needed:  YES  NO

- Entyvio®** (vedolizumab) infuse Entyvio in NS 250 ml over 30 minutes as directed  
 Initial Dose: 300 mg IV @ 0, 2, 6 weeks  Maintenance Dose: 300 mg IV every 8 weeks
- Humira®** (adalimumab)  40 mg Prefilled Syringe OR  40 mg Pen Auto Injector  Citrate/buffer free  
 Starter Kit: 160 mg SC on day 1, 80 mg on day 15, then 40 mg every other week  
 Maintenance Dose: 40 mg SC every other week
- Remicade®** (infliximab) OR  **Avsola®** OR  **Inflectra®** OR  **Renflexis®** Infuse in NS 250 ml over 2 hours  
 Initial Dose:  5 mg/kg @ 0, 2, 6 weeks  
 Maintenance Dose:  5 mg/kg every 8 weeks  10 mg/kg every 8 weeks  
 Other Remicade dosing: \_\_\_\_\_
- Rinvoq®** (upadacitinib)  
 Initial Dose: 45 mg PO once daily for 8 weeks  
 Maintenance Dose:  15 mg PO once daily  30 mg PO once daily
- Simponi®** (golimumab)  
 Initial Dose: Inject 200 mg SC at Week 0, followed by 100 mg at Week 2 then every 4 weeks  
 Maintenance Dose: Inject 100 mg SC every 4 weeks
- Stelara®** (ustekinumab)  
 Initial Single Dose IV x 1 hour:  <55 g: 260 mg  56-85 kg: 390 mg  >85 kg: 520 mg  
 Maintenance Dose: 90 mg subcutaneously every 8 weeks
- Xeljanz®** (tofacitinib)  
 Initial dose: 10 mg PO twice daily for at least 8 weeks  
 Maintenance Dose:  5 mg PO twice daily  10 mg PO twice daily
- Zeposia®** (ozanimod)  
 Initial Dose: 0.23 mg PO once daily on days 1 through 4; then 0.46 mg PO once daily on days 5 to 7  
 Maintenance Dose: 0.92 mg PO once daily starting on day 8

Quantity Prescribed:  QS 30 days  Other: \_\_\_\_\_ Refills Authorized:  0  1  2  3  6  11  Other: \_\_\_\_\_

Physician Signature (no stamps): \_\_\_\_\_ Date: \_\_\_\_\_

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.